Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Acrux Ltd. (OTC: ARUXF).

Full DD Report for ARUXF

You must become a subscriber to view this report.

Recent News from (OTC: ARUXF)

Acrux Ltd. 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Acrux Ltd. in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: February, 21 2018 14:47
Patent Dispute Eli Lilly And Acrux: Update And Opportunity?
Yesterday I wrote about bad news for Eli Lilly (LLY) and Acrux (ASX:ACR) (ARUXF) for their testosterone replacement therapy. The US District Court for the Southern District of Indiana declared the core protective patents for Axiron, delivery of testosterone through the armpit, to be invalid....
Source: SeekingAlpha
Date: August, 24 2016 08:52
Patent Dispute Off The Rails For Eli Lilly And Acrux
Biotech is full of risk and nowhere is that more apparent than in the area of intellectual property protection. Patents define the value of blockbuster drugs, but they only offer protection if they survive challenge. Last year Eli Lilly (LLY) and Acrux (ASX:ACR)(ARUXF) filed a lawsuit agai...
Source: SeekingAlpha
Date: August, 23 2016 03:28


About Acrux Ltd. (OTC: ARUXF)

Logo for Acrux Ltd. (OTC: ARUXF)

Not available


Contact Information



Current Share Structure

  • Market Cap: $18,314,637 - 05/11/2018
  • Issue and Outstanding: 166,496,700 - 10/21/2011


Daily Technical Chart for (OTC: ARUXF)

Daily Technical Chart for (OTC: ARUXF)

Stay tuned for daily updates and more on (OTC: ARUXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ARUXF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

OTC Report



Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ARUXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ARUXF and does not buy, sell, or trade any shares of ARUXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: